TRT and Fertility: Using HCG to Preserve Sperm Production
Testosterone replacement suppresses sperm production within months. HCG and selective protocols can preserve fertility — here's how the biology and the medication interact.
Standard testosterone replacement shuts down the body's own testosterone production by suppressing LH and FSH from the pituitary. FSH is the signal that drives sperm production — without it, spermatogenesis declines, often within 4–6 months. For men who want to preserve fertility, this is a planning problem worth solving in advance.
How HCG works
Human chorionic gonadotropin mimics LH at the testicular level. It maintains testicular function — both intratesticular testosterone production and the local environment required for spermatogenesis — even while exogenous testosterone is suppressing the pituitary signal.
The standard fertility-preserving protocol
500–1,000 IU of HCG subcutaneously, 2–3 times per week, alongside the usual testosterone cypionate dose. This typically preserves testicular volume, intratesticular testosterone, and sperm parameters for the majority of men.
What the data shows
A widely cited 2013 study by Coviello et al. showed that HCG at 500 IU every other day maintained intratesticular testosterone at 25% of baseline despite full exogenous testosterone suppression — sufficient for spermatogenesis in most men.
What HCG won't do
HCG does not restore an already-shut-down fertility status as quickly as it preserves an active one. Men who have been on TRT without HCG for years may require a more involved restart protocol — clomiphene, hMG, or assisted reproductive options — and should plan for a 6–12 month timeline.
When to bank sperm
If you are considering TRT and biological children may matter to you in the future, sperm banking before starting therapy is the simplest insurance policy. It removes the dependence on protocol compliance and the variability of restart success.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Coviello AD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90:2595-2602.— Journal of Clinical Endocrinology and Metabolism, 2005.
- 2.Crosnoe LE et al. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2:106-113.— Translational Andrology and Urology, 2013.
- 3.Bhasin S et al. Testosterone Therapy in Men with Hypogonadism: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.— Endocrine Society, 2018.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
